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2 The International Normalised Ratio (INR), a standardised method of reporting the prothrombin time, 
3 
4 can be a surrogate marker of the vitamin K dependent coagulation pathways. 
6 
7 
8 Objective: To evaluate the relationship between INR measurements in the first 48 hours of life, and 
9 
10 subsequent development of Intra Ventricular Haemorrhage (IVH) in extremely preterm infants. 
11 
12 
13 Methods: Single centre retrospective, observational cohort study of infants born at less than 28 
14 
15 
16 weeks gestation. Main outcome measure was defined as the degree of IVH seen on cranial 
17 
18 ultrasound examinations at day 7 postnatal age. 
19 
20 
21 Results: 109/200 infants (mean gestational age 25.2 weeks (SD 1.27)) had coagulation results 
22 
23 
24 available. 26/109 developed IVH. Increased INR was associated with increased risk of a severe IVH 
25 
26 OR 5.66 (1.56-20.59; p=0.008) and OR 6.50 (1.65-25.62; p=0.008) adjusted for gestation, birth weight 
27 
28 and gender. INR was strongly associated with severe IVH in infants who did not receive blood 
30 





36 Conclusion: An elevated INR in the first 48 hours of life may be useful to identify preterm infants at 
38 





























3 Disruption  of  haemostasis  in  preterm  neonates  remains  a  significant  concern  because  of  the 
4 
5 potential contribution  to  the  development or extension  of  intra-ventricular  haemorrhage  (IVH) in 
7 
8 extremely preterm infants [1]. The causative elements in the development of IVH are complex and 
9 
10 inter-related but platelet and coagulation function remain an accepted element despite conflicting 
11 
12 
13 evidence [1-4]. We continue to examine this issue because IVH is a major predictor of the long-term 
14 
15 neurodevelopmental outcome following extremely preterm birth [5]. 
16 
17 Altered haemostasis has been a recognised issue within the care of preterm infants since 1957 [6]. 
18 
19 
20 Diminished levels of coagulation proteins have been reported in the fetal and neonatal population, 
21 
22 [1, 7-10]. In addition to this immaturity of haemostasis, other factors that can often precipitate 
23 
24 preterm delivery, such as placental dysfunction, Intra-Uterine Growth Restriction, or Foeto-maternal 
26 
27 infection, are all likely to influence the haemostasis system directly [10-13]. In particular, co-existing 
28 
29 perinatal inflammation has been demonstrated to adversely affect the Vitamin K dependent 
30 
31 
coagulation pathway (related to low concentrations of clotting factor VII) [10,11]. 
33 
34 The understanding of the development of the coagulation profile in infants born extremely preterm, 
35 
36 less than 28 weeks gestation is still incomplete. One of the challenges to research in this area has 
37 
38 
39 been the difficulty in establishing ‘normative’ data ranges for haematological parameters in 
40 
41 extremely preterm infants, partly because extremely preterm birth is not a ‘normative’ state [10] 
42 
43 and furthermore neonatal clotting studies are dependent on sample collection and regularly 
44 
45 
46 affected by activation of clotting during slow sampling [14]. 
47 
48 Studies on coagulation profile in extremely preterm infants have either looked at individual 
49 
50 coagulation factor levels [10,11,13,15,16] or coagulation profile measurements [17,18]. 
52 
53 Several studies have looked at coagulation tests and subsequent development of IVH in neonates 
54 
55 describing alterations in the Vitamin K dependent coagulation system and subsequent risk of IVH [1, 
56 
57 
58 11,15,17-21]. A recent study supports the assumption that this association seems to be influenced 
59 

















From the clinical point of view it seems crucial to provide a measure estimating the Vitamin K- 
1 
2 dependent   coagulation  system   in  infants   following  preterm   delivery,   focussing  on potentially 
3 
4 




9 Currently it is not common practice in UK neonatal units to measure individual coagulation factor 
10 
11 
12 levels  at   routine   lab  testing  within  the  first   days  of   life  [24]. First line coagulation profile 
13 
14 measurements would usually include PT (Prothrombin Time), APTT (Activated Partial 
15 
16 Thromboplastin Time) and Fibrinogen [12]. The assessment of INR would be of particular interest, as 
18 
19 it presents a standardised method of reporting the PT. INR was devised to overcome inter-laboratory 
20 
21 variability due to thromboplastin sensitivity during PT testing. INR is calculated: patient PT/control 
22 
23 
PT to the power of the international sensitivity index (ISI) [25]. INR and PT have been shown to be 
25 
26 indicative of the Vitamin K dependant “extrinsic” coagulation pathway in neonates [7]. The 
27 
28 association between INR values and development of IVH has been reported in a cohort of extremely 
29 
30 
31 preterm infants [18] supporting the assumption that INR could play a role in the understanding of 
32 
33 the causative relation of prothrombin related haemostasis to risk of IVH. 
34 
35 The primary aim of this work was therefore to investigate the association between coagulation 
36 
37 
38 measures in preterm infants and the risk of developing IVH and secondarily to evaluate the influence 
39 



































Materials and Methods 
1 
2 Population: All infants born at less than 28 completed weeks gestational age and admitted within 48 
3 
4 hours of birth to Southmead Hospital, Bristol, UK, tertiary neonatal intensive care unit, between 
6 
7 March 2008 and January 2012, were eligible for this study (n=218). Infants were excluded if they did 
8 
9 not have ultrasound data recorded (n=18) or had no coagulation studies performed in the first 48 
10 
11 
hours of life (n=91), leaving 109 infants for the main analysis (N.B. Not all infants had all measures of 
13 
14 coagulation recorded and so denominators vary). 
15 
16 
17 Exposure measures: All coagulation studies were performed as part of the routine admission blood 
18 
19 
sampling and analysed using the Sysmex CS-2100 analyser (Sysmex UK Ltd, Milton Keynes, UK). 
21 
22 Quality control of the coagulation testing was performed using Siemens Actin FS for APTT (n=479; 
23 
24 mean 26.18 sec (SD 0.85 sec)), Siemens Innovin for PT (n=494; mean 11.18 sec. (SD 0.43 sec.)) and 
25 
26 
27 Siemens Thrombin for fibrinogen (n= 214; mean 2.57 mg/dl (SD 0.11 mg/dl)), (Siemens, Erlangen, 
28 
29 Germany) [26]. Haematocrit (HCT), total white cell count (WBC), total platelet count were analysed 
30 
31 using Sysmex XE-2100 analyser (Sysmex UK Ltd, Milton Keynes, UK). INR was calculated using a 
32 
33 
34 reagent with mean normal PT and international sensitivity index derived from internationally 
35 
36 calibrated reference pooled adult plasmas. The reference range of the INR test for non-coagulated 
37 
38 patients (whole blood, citrate tube) was 1.0-1.3. Where infants had multiple samples, the first 
40 
41 recorded sample taken after admission to the unit was used. Infants were only included in the 
42 
43 analysis if they had coagulation parameters measured within the first 48 hours of life. According to 
44 
45 
46 the unit protocol all preterm infants received Vitamin K (0.4mg/kg intramuscular) on admission to 
47 
48 the neonatal intensive care unit [27]. Therefore, all of the coagulation parameter measurements 
49 




54 Outcome measures: Cranial Ultrasound Imaging was performed with a Philips HD11XE US machine 
55 














classified according to Volpe [28] at 7 days of age. All images were independently reviewed and 
1 
2 categorised by one of the researchers (AH). 
3 
4 
5 Demographics and covariates: Antenatal and perinatal characteristics of the study population were 
7 
8 collected  from  patient electronic  and written  medical  records.  A  full  course  of  antenatal steroid 
9 
10 treatment was defined as administration of two doses of 12mg betamethasone more than 24 hours 
11 
12 
13 prior to delivery. Data was collected regarding the frequency of administration of blood products 
14 
15 (including packed red cells (PRC), platelets, cryoprecipitate and fresh frozen plasma) in the first 48 
16 




21 Data analysis: 
22 
23 
24 Initially patient characteristics were derived and then a comparison of demographics between those 
25 






32 The association between coagulation results and gestation was investigated, as was the effect of 
33 
34 being Small for Gestational Age (SGA birth weight below the 9th centile for gestation). The 
35 
36 
proportion of infants with IVH was calculated and the univariable association between coagulation 
38 
39 measures and risk of IVH derived. Finally a logistic regression model was developed assessing the 
40 
41 association between coagulation measures (as a continuous variable) and severe IVH (grade 3- 
42 
43 
44 4[28]). This was assessed unadjusted and adjusted for gestational age, birth weight and gender; 
45 
46 clinical chorioamnionitis and initial CRP value. In sensitivity analysis the possible of effect of blood 
47 




52 The data did not follow a normal distribution so comparisons were performed using t-test, Chi- 
53 
54 square or Mann-Whitney U as appropriate. All analyses were conducted with Stata 10 software 
55 
56 (Stata Corp, College Station, TX), and results are presented as number (percent), mean (SD), or 
57 
58 












Ethical approval for all data collection was obtained from the North West NRES committee, UK 
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2 Demographic information on eligible infants with cranial ultrasound results is given in Table 1, split 
3 
4 by those with, or without coagulation measures (n=200); 91 infants did not have coagulation studies 
6 
7 reported within the first 48 hours of life. When compared to the infants who did have coagulation 
8 
9 studies  available,  these  infants  did  not  differ  in  major  perinatal  characteristics  except  a  lower 
10 
11 
incidence of severe IVH (23.8% versus 7.7%; p=0.008) and a higher incidence of complete antenatal 
13 
14 steroids (52.8% versus 72.2%; p=0.005). In particular there was no significant difference between the 
15 
16 groups with respect to the CRIB score, reflecting no significant difference in risk of early perinatal 
17 
18 
19 morbidity [29]. 
20 
21 
22 Infants of lower gestations had higher fibrinogen (p=0.004) and platelet values (p=0.027), and some 
23 
24 evidence of higher white blood cell counts (p=0.051), but there was little evidence of an association 
25 
26 
27 between with gestational age and INR (p=0.439) or HCT (p=0.451) measures (Table 2). SGA infants 
28 
29 had lower fibrinogen levels (0.7mg/dL vs 1.8mg/dL; p=0.0007) but similar INR (p=0.232) and APTT 
30 
31 levels to well grown infants (p=0.496). In total 60 (55%) of infants had no evidence of IVH 
32 
33 
34 demonstrated on the day 7 cranial ultrasound, while 26 (23.9%) had evidence of severe IVH (grade 
35 
36 3-4). There was little evidence of an association between fibrinogen and APTT plasma levels and the 
37 





44 Overall there was weak evidence that infants that received blood products had a higher risk of a 
45 
46 severe IVH (21/26 (80.8%) vs 5/26 (19.2%), p=0.069), (table 4). Substitution of FFP and / or 
48 
49 cryoprecipitate was associated with incidence of severe IVH (table 4). No significant difference was 
50 
51 found for platelet substitution or PRBC transfusion and incidence of severe IVH in the study cohort. 
52 
53 
54 The initial INR was not different for those who received blood products (1.5 (1.3-1.8)) or not (1.5(1.4- 
56 
57 1.8); p=0.358). Initial fibrinogen concentration were significantly higher and initial platelets were 
58 












In the logistic regression model an increased INR was associated with increased risk of a severe IVH 
1 
2 in the unadjusted (OR 5.66 (1.56-20.59), p=0.008) and model adjusting for gestation, birth weight, 
3 
4 
5 gender, clinical chorioamnionitis and initial CRP (OR 5.994 (1.49-24.07), p=0.012), but little evidence 
6 
7 for an association between APTT (adjusted OR 1.02 (1.00-1.04), p=0.095) or fibrinogen (adjusted OR 
8 




13 INR remained strongly associated with severe IVH in infants who did not receive blood products (OR 
14 
15 64.60 (1.35-3081.25)), p=0.035), but not in those who did (OR 2.93 (0.67-12.71), 
16 
17 p=0.151)(pinteraction=0.086). Due to missing data for APTT and fibrinogen, all infants who had severe 
18 
19 
























































3 We present a retrospective observational study examining coagulation parameters taken during the 
4 
5 first 48 hours of life in a cohort of extremely preterm infants. Participants had a mean gestation of 
7 
8 25 weeks, and therefore a high risk of developing IVH; this is reflected in the incidence of severe  IVH 
9 
10 (23.9%) in the study population. We report an association between an elevated INR and subsequent 
11 
12 
13 development of IVH and some additional evidence that the delivery of blood products may reduce 
14 
15 this risk. Although there is evidence that alterations in prothrombin related coagulation is associated 
16 
17 with bleeding in newborn infants [11,17,18,20] this is, to the best of our knowledge, the first study 
18 
19 
20 to report this association in a cohort of this size and this degree of prematurity, or evidence that 
21 
22 early delivery of blood products can reduce IVH risk. 
23 
24 
25 The physiology of haemostasis during foetal development has been thought to change rapidly over 
26 
27 
28 each week of gestation [7,8] necessitating multiple sets of reference ranges. Many of the reference 
29 
30 ranges for ‘normal’ data in extremely preterm infants are derived from measurements of 
31 
32 coagulation proteins in foetal samples [7-9]. However, extremely preterm infants as reflected in our 
33 
34 
35 study cohort are likely to differ physiologically from foetuses in utero at the same gestation, because 
36 
37 perinatal factors likely influence on the coagulation protein concentrations measured following 
38 
39 preterm delivery [10,13]. This may result in clinicians seeing coagulation result figures outside any 
41 
42 given reference range [17]. The challenge is to know at what level these abnormal results may 
43 
44 increase the risk of IVH and adverse outcome in our patient population, and indeed what we may do 
45 
46 
47 to prevent or ameliorate this risk. 
48 
49 
50 Previous studies have suggested that the lower the gestation, the more impaired the coagulation 
51 
52 pathways [1,6,7,10,13]. However, our data did not confirm this correlation between impaired 
53 
54 
55 coagulation and shorter gestational age. It may be that our data differed from other studies, as 
56 
57 coagulation studies were taken from our cohort of infants after the administration of Vitamin K, 
58 















recent published data [17] our data did not support the assumption that coagulation is significantly 
1 
2 altered  by  ‘being  small  for  gestational  age’  as  suggested  earlier  [13].  A  previous  study  [18] 
3 
4 
5 demonstrated a correlation between INR in the first 24 h of life and the occurrence of IVH in preterm 
6 
7 infants categorized by birth weight less 1500g. In this study, INR, PT and PTT values were significantly 
8 
9 associated to birth weight. In contrast to this finding, the association of INR and severe IVH in the 
10 
11 
12 adjusted regression model in our study was not significantly influenced by either gestational age or 
13 
14 birth weight. 
15 
16 
17 Our study supports the assumption that INR in the assessment of prothrombin-related haemostatic 
18 
19 
20 profile might be of relevance to the neonatal population. This is important for two reasons: firstly 
21 
22 the “extrinsic” coagulation pathway has been demonstrated to be particularly deficient in extremely 
23 
24 preterm infants [10,11], and secondly, this pathway seems to be particularly implicated in the 
26 
27 pathogenesis of IVH in preterm infants [20]. 
28 
29 
30 The INR itself is calculated from the PT and PT measures time to fibrin clot formation in vitro, it is 
31 
32 therefore not a global measure of coagulation. As part of an initial assessment of coagulation in 
33 
34 
35 preterm infants, the INR has inherent limitations because it is derived by comparison with a ‘normal’ 
36 
37 control value. Because of the difficulties defining normative data in extremely preterm infants, the 
38 
39 control value is derived from adult data, however the “normal” control value is a constant value in 
41 
42 relation to the PT as explained in the Materials and Methods section above [25]. As such, its 
43 
44 interpretation and clinical meaning can remain the same as if one were interpreting the PT. 
45 
46 
47 In the presented extremely preterm cohort, each increase in INR by 1.0 had an odds ratio of a severe 
49 
50 IVH of 5. This is, given the adverse neurodevelopmental outcome associated with severe IVH [28], 
51 
52 potentially a clinically important finding. This defect in the extrinsic pathway in preterm neonates 
53 
54 
55 has been considered for potential for intervention to prevent IVH. One such example would be 
56 
57 antenatal administration of Vitamin K, much as we administer antenatal steroids to benefit the 
58 













the Cochrane review on this topic concluded that ‘Vitamin K administered to woman prior to very 
1 
2 preterm birth has not been shown to significantly prevent peri-ventricular haemorrhage in preterm 
3 
4 
5 infants or to improve neurodevelopmental outcomes in childhood’ [32]. 
6 
7 
8 We  observed  that   there  was   some   evidence   that  the  early administration  of  blood  products 
9 
10 influenced the association between increased INR and increased risk of severe IVH.   Although the 
11 
12 
13 relationship was only of weak statistical significance, it still may be a clinically important finding as a 
14 
15 risk attenuation with targeted blood product administration in prevention of IVH in extremely 
16 




21 In addition to improving the concentrations of vitamin K dependent coagulation factors, which might 
22 
23 prevent the initial occurrence of a haemorrhage, or limit its extension; we would suggest that the 
24 
25 administration of blood products guided by functional echocardiography including assessment 
26 
27 
28 superior vena cava flow [33] (in our unit usually in a volume of 15-20 ml/kg,) provides colloid, 
29 
30 increases intravascular volume, and contributes to haemodynamic stability at a very crucial time [3]. 
31 
32 However, previous studies failed to demonstrate a benefit of prophylactic volume expansion, in 
33 
34 
35 particular using fresh frozen plasma concentrates on the incidence of IVH in preterm infants [34]. 
36 
37 
38 We were however limited by the retrospective study design, and the assessment of coagulation 
39 
40 parameters may well have been subject to selection bias by the attending clinician at the time. 
41 
42 
43 However, our data (Table 1) demonstrates no significant difference in most of the perinatal factors 
44 
45 (including gestational age, birth weight, CRIB score, Apgar score, multiple delivery and mode of 
46 
47 delivery) between the infants who had coagulation results available in the first 48 hours of life, and 
49 
50 those that did not. The only significant finding was that those infants who had their coagulation 
51 
52 parameters measured were less likely to have received a full course of antenatal steroids. Since 
53 
54 
55 antenatal steroids have been demonstrated to be protective against developing IVH [35], this, 
56 
57 together with the degree of immaturity of our cohort, might have contributed to the comparably 
58 



























When considering the group of infants who received blood products for their abnormal  coagulation, 
1 
2 this may have also been subject to selection bias based upon decisions made by the attending 
3 
4 
5 clinician at the time.   It is possible that the attending clinician would have been more likely to 
6 
7 administer  blood  products  to  those  babies  who  were  felt  to  be  at  higher  risk  of  IVH.  If  this 
8 
9 hypothesis is true, then this would further strengthen our findings that administration of blood 
10 
11 
12 products to extremely preterm infants with abnormal coagulation parameters in the 48 hours of life 
13 
14 may be associated with attenuation in the risk of development of severe IVH. 
15 
16 
17 The association between administration of coagulation factor concentrates [36,37] or fresh frozen 
18 
19 
20 plasma [34, 38-40] and risk of severe IVH has been looked at previously, but may well warrant a 
21 
22 return of focus to this subject, both into the exact values at which coagulation abnormalities should 
23 
24 be acted upon in this group of extremely vulnerable infants, but also into which blood products 
26 
27 would be of most benefit in reducing IVH risk. The data presented add to the understanding on 
28 
29 coagulation in extremely preterm infants, hereby supporting the idea of a risk stratified coagulation 
30 
31 
screening with focus on prothrombin dependent coagulation in a group of infants that are at 
33 
34 particularly high risk of IVH, aiming for prevention or limitation of the extension of an IVH. 
35 
36 
37 In summary, an elevated INR in the first 48 hours of life is associated with the development of IVH in 
38 
39 extremely preterm infants and this relationship may be attenuated by the early administration of 
41 
42 blood products. Future studies should focus on defining the exact coagulation parameter limits 
43 
44 where treatment should be offered, and which blood product may offer the most therapeutic 
45 
46 
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Clinical Risk Index for Babies Score [29], ** SVD = Spontaneous Vaginal Delivery, *** A/N Steroids = a 
Full course of antenatal steroids (see Methods). 
Values are number (%), mean (SD) or median (IQR) 
Measure Coagulation 
results available 




(n = 91 ) 
p value 
Gestational age (weeks) 25.2 (1.27) 25.3 (1.14) 0.4218 












CRIB score* 12.1 (2.4) 11.5 (2.6) 0.2186 
Apgar at 5 minutes 8 (6-9) 7 (7-9) 0.1140 
Males 62 (56.9%) 48 (52.8%) 0.558 
Born by SVD** 55 (50.9%) 41 (45.1%) 0.636 
Multiple birth 31 (28.4%) 22 (24.2%) 0.496 





Table 2. Coagulation studies and full blood count in first 48 hours of life. Data split by completed 



























Measures are given as median and inter-quartile range (IQR) ; * n= number of complete coagulation 
studies available for analysis. 
Gestational 































































































Table 3: Coagulation parameters and diagnosis of IVH: Study population grouped according to 
grade of IVH on Day 7 cranial ultrasound [28]: 
 
Grade of IVH Fibrinogen 
(mg/dl) 
(n = 85)* 
INR 
(n = 109)* 
APTT (s) 
(n=91)* 
0 (n=60) 1.4 (0.8-3.6) 1.5 (1.3-1.7) 52.4 (48.2-63.5) 
I (n=10) 1.2 (0.7-1.8) 1.6 (1.3-1.8) 49.8 (43.3-58.6) 
II (n=13) 2.4 (1.8-3.8) 1.6 (1.4-2.0) 54.9 (41.8-76.5) 
III (n=6) 0.6 (0.5-4.8) 1.9 (1.7-2.3) 63.9 (52.0-89.3) 
IV (n=20) 1.6 (1.1-4.1) 1.7 (1.4-1.9) 59.9 (50.4-73.6) 
Ptrend 0.959 0.003 0.109 
Measures are given as median and inter-quartile range (IQR); * Number (n) of performed coagulation 




Table 4: Substitution of blood products (no – bp; ffp, cryo, plts, prbc ) and 
diagnosis of severe IVH: Study population grouped according to grade of 
IVH on Day 7 cranial ultrasound [28]: 
 
Blood product Severe IVH 
Yes 
(n = 26) 
Severe IVH 
No 




any- blood product 
Yes/No; (n) 
5/21 32/51 0.069 
FFP 
Yes/No; (n) 
15/11 13/70 0.0001 
Cryoprecipitate 
Yes/No; (n) 
1/25 1/82 0.381 
ffp and/or cryo 
Yes/No; (n) 
15/11 14/69 0.0001 
Plts 
Yes/No; (n) 
2/24 3/80 0.386 
PRBC 
Yes/No; (n) 
17/9 41/42 0.154 
 
